Nature Medicine

Pandemic Fatigue and Vaccine Hesitancy Continue to Affect Global Public Health, New 23-country Study in Nature Medicine Reports

Retrieved on: 
måndag, april 29, 2024
Lazarus, Health policy, Nature Medicine, Vaccine hesitancy, Risk, Public health, World Health Organization, CUNY, COVID-19 vaccine, Health, Death, Vaccine, Immunization, Science, Global Health, Vaccine-preventable diseases, Trust, City University, Health communication, Government, COVID-19, Prevalence

NEW YORK, April 29, 2024 /PRNewswire/ -- While it found that global uptake of at least one COVID-19 vaccine dose was robust, a new survey published today in Nature Medicine revealed mixed signals about the current acceptance of vaccines generally, especially COVID-19 boosters. The new survey of 23,000 respondents from 23 countries representing more than 60% of the world's population is the fourth in series of studies led annually since 2020 by a team from the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH).

Key Points: 
  • "They represent major obstacles for health practitioners struggling to meet the urgent need to get people caught up on routine immunizations and ready to face the next pandemic."
  • Reported global uptake of at least one COVID-19 vaccine dose rose last year to 87.8%, as compared to 36.9% in 2021 and 70.4% in 2022.
  • In addition, documented spillover effects on routine immunization raise the threat of the reemergence of other childhood and adult vaccine-preventable diseases.
  • The most trusted sources were "my doctor or nurse" and the World Health Organization, averaging 6.9 and 6.5, respectively.

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date

Retrieved on: 
torsdag, april 25, 2024
FDA, De novo, Partnership, EUR, TAP, Spinal cord, Lead, BDD, Defense, American Academy, Class, MJFF, Equity, Safety, ARC, BCI, Euronext, Research, University, Hemiunu, Global marketing, Government, SCI, Nature Medicine, Paralysis, Movement, SDVOSB, Pharmaceutical industry

The Company is developing a portfolio of ARC-IM Leads, each optimized for placement on a different area of the spinal cord.

Key Points: 
  • The Company is developing a portfolio of ARC-IM Leads, each optimized for placement on a different area of the spinal cord.
  • Also in November, ONWARD Medical research partner .NeuroRestore was awarded a $1 million grant from The Michael J.
  • In Q2, Bryan, Garnier & Co reinitiated research coverage of ONWARD Medical following the appointment of a new equity research analyst.
  • For 2023, the Company reported an operating loss of EUR 35.5M compared to EUR 32.0M in 2022.

RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers

Retrieved on: 
tisdag, april 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Nature Medicine, NKI, Cell, Nature Biotechnology, TILS, Research, Patient, Netherlands Cancer Institute, Synthetic biology, Discovery, Neoplasm, TCR, Growth, Gene, Fine chemical

RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.

Key Points: 
  • RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.
  • The publication is titled “ Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening ”.
  • With the help of RootPath’s innovative synthesis technology, we now improved the throughput of this approach by a factor of 100.
  • The company will soon offer TCR gene synthesis and screening services commercially, as reported in the study.

First Ascent Biomedical’s New Study Shows Functional Precision Medicine Platform Identifies Effective Treatments for 83 Percent of Children with Difficult-to-Treat Cancers

Retrieved on: 
måndag, april 22, 2024
Pharmaceutical, Research, Children, Oncology, Software, Artificial Intelligence, Hospitals, Consumer, Genetics, Data Management, Stem Cells, Science, Technology, Clinical Trials, General Health, Biotechnology, Health, Health Technology, Nature Medicine, Adolescence, FIU, DST, Genomics, Florida International University, Partnership, Cancer, Patient, Doctor of Philosophy, Hope, FPM

First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.

Key Points: 
  • First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.
  • The study identified specific and effective therapeutic options for 83% of study participants with pediatric relapsed or treatment-resistant cancers.
  • “After a decade of research, this study validates using FPM data to inform the next line of therapy for children who have exhausted standard-of-care options.
  • First Ascent Biomedical’s Functional Medicine Platform (FPM) is a first-in-kind AI-driven drug prediction platform that integrates DNA/RNA sequencing, mutation analysis, and drug sensitivity testing of cancer cells.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
fredag, april 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
torsdag, mars 7, 2024
T cell, Glioblastoma, Arms, ICT, ICV, Traffic barrier, Toxicity, Headache, Biopsy, DSM-IV codes, Cerebrospinal fluid, City, Cancer, Central nervous system, CXCL10, TME, Cerebral edema, Dual, Hope, GBM, Safety, CXCL9, Fatigue, Hypertension, Translation, CNS, Tumor microenvironment, Patient, Arm, Spinal cord, Survival, Brain, Nature Medicine, Infrared spectroscopy correlation table, Vaccine

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Retrieved on: 
måndag, februari 26, 2024
BRAF, Pfizer, Research, New Drug Application, Doctor of Philosophy, MD, Investment, FDA, Food, Priority review, Day One, Event, Patient, Medicine, Clinical trial, Nature Medicine, NDA, Head, Ageing, MEK, Pharmaceutical industry

BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2023 financial results and highlighted recent corporate achievements.

Key Points: 
  • “We have a monumental year ahead of us at Day One with the upcoming PDUFA date for tovorafenib,” said Jeremy Bender, Ph.D., chief executive officer of Day One.
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.
  • In November 2023, Nature Medicine published the registrational Phase 2 FIREFLY-1 trial results investigating tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma (pLGG).
  • In the fourth quarter of 2023, Day One continued its commercial preparedness for the approval and launch of tovorafenib with the hiring of 18 sales representatives in the U.S.

Limbic Raises $14M to Bring AI-Powered Mental Health Support, Proven in the World’s Largest Public Health System, to U.S. Providers

Retrieved on: 
tisdag, mars 5, 2024
Technology, Mental Health, Medical Devices, LGBTQ+, Health Technology, Health, Consumer, General Health, Artificial Intelligence, Mental health, AI, Intelligence, Generative, NHS, Khosla Ventures, Synthetic media, Supercell, Patient, Acceleration, Mental, United, Burnout, Workforce, Nature Medicine, Vinod Khosla, Brain, Nursing

Limbic’s mental health AI has been used by over 260,000 patients across the United Kingdom’s National Health Service (NHS) Talking Therapies.

Key Points: 
  • Limbic’s mental health AI has been used by over 260,000 patients across the United Kingdom’s National Health Service (NHS) Talking Therapies.
  • Limbic’s clinical AI has demonstrated increased access to mental health services, acceleration in patient onboarding, reduced wait times, and improved quality of care.
  • The funding will expand the availability of Limbic’s clinical mental health AI to U.S. health providers.
  • This included a 179% increase among people who identified as non-binary, 39% for Asian and 40% for Black mental health patients.

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
onsdag, februari 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CCNE1, Quarter, Adolescence, Research, Arm, PPP2R1A, PARP, FBXW7, Net, FOLFIRI, AACR, Conference, BMS, ADP, PLK4, Clinical trial, Safety, Therapy, Patient, RECIST, Nature Medicine, IND, ATR, WEE1, Partnership, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Repare will sponsor the global clinical trial as a new arm in the ongoing MYTHIC trial, with costs being shared equally by Debiopharm and Repare.
  • Disclose additional camonsertib clinical development plans beyond the TRESR and ATTACC clinical trials sponsored by Repare in the second quarter of 2024.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents, and marketable securities: Cash, cash equivalents, and marketable securities as of December 31, 2023 were $223.6 million.

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Retrieved on: 
tisdag, februari 6, 2024
Biotechnology, Paper, SAN, Cell, Research, VEGF, Therapy, Ageing, Environment, Patient, Diabetic retinopathy, Hyperglycemia, Unity Biotechnology, Retina, Homeostasis, Visual acuity, UBX, Cellular senescence, Diabetes, Endothelium, DME, University, Eye, Metalloproteinase, Nature Medicine, Université de Montréal, Pharmaceutical industry

Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.

Key Points: 
  • Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.
  • This can lead to fluid accumulation and retinal thickening – a key feature of DME.
  • They demonstrated that these senescent cells contribute to loss of barrier function, which can cause leaky blood vessels.
  • This research further supports the potential for senolytic medicines to address the significant unmet need with current standard of care.”